Figure 7.

Post-treatment plasma mitochondrial DNA concentrations are reduced in patients who respond to pirfenidone. Relative to subjects who did not respond to pirfenidone (nonresponders; right), as demonstrated by a greater than 10% reduction in FVC percent predicted after 1 year of treatment, subjects who responded to pirfenidone by retaining stable FVC after 1 year of treatment (responders; left) showed a significant decline in their change in median plasma MT-ATP6 concentration, as compared with their baseline MT-ATP6 concentration, after 3 months of therapy. Data are presented graphically as change in median with interquartile range of MT-ATP6 copies per microliter of plasma.